Full-Time

Manufacturing Engineer 3

BiVACOR

BiVACOR

51-200 employees

Develops magnetically levitated total artificial heart

Compensation Overview

$120k - $127k/yr

+ Discretionary Bonus

Huntington Beach, CA, USA

In Person

On-site at Huntington Beach HQ. Relocation benefits not available.

Category
Mechanical Engineering (1)
Required Skills
Six Sigma

Get referred to BiVACOR

Find people who can refer or advise you

Requirements
  • BS in Mechanical, Electrical, Biomedical or Manufacturing Engineering, MS desirable (or equivalent)
Responsibilities
  • Design, develop, and improve manufacturing processes to enhance efficiency and product quality.
  • Implement Lean and Six Sigma methodologies to reduce waste and optimize workflows.
  • Implement automation and advanced manufacturing techniques where applicable.
  • Design, procure, and validate equipment, tools, and fixtures for manufacturing processes.
  • Ensure proper calibration and maintenance of manufacturing equipment.
  • Conduct process validations (IQ, OQ, PQ) and ensure compliance with FDA, ISO 13485, and GMP standards.
  • Support NC/CAPA investigations and implement corrective actions.
  • Create and maintain manufacturing documentation, including BOMs, work instructions, and process flow charts.
  • Prepare technical reports and documentation for audits and regulatory submissions.
  • Analyze and resolve manufacturing issues, including CAPAs and non-conformances.
  • Identify opportunities for process improvements and implement solutions to enhance productivity and reduce costs.
  • Work closely with cross-functional teams, including R&D, Quality Assurance, and Supply Chain, to support product development and manufacturing goals.
  • Provide technical support to production teams and train operators on new processes and equipment.
Desired Qualifications
  • MS in Mechanical, Electrical, Biomedical or Manufacturing Engineering (or equivalent)

BiVACOR is a clinical-stage medical device company developing the BiVACOR Total Artificial Heart (TAH) to replace a failing heart. The device is a compact, titanium implant that uses a single magnetically levitated rotor to pump blood to the lungs and the rest of the body, eliminating valves and mechanical bearings to reduce blood damage. It serves as a bridge-to-transplant and aims to become a long-term (permanent) alternative to heart transplantation. BiVACOR operates in the cardiovascular medtech space, pursuing regulatory approval through preclinical and clinical trials, including an FDA Breakthrough Device Designation and an Early Feasibility Study. Its strategy includes expanding from Australia to the US, securing funding, and advancing toward commercialization to address the large unmet need in end-stage heart failure.

Company Size

51-200

Company Stage

Grant

Total Funding

$46.7M

Headquarters

Houston, Texas

Founded

2008

Get referred to BiVACOR

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA Breakthrough designation in May 2025 accelerates regulatory review for severe biventricular or univentricular heart failure cases.
  • 100% bridge-to-transplant efficacy was achieved across all five patients in the FDA Early Feasibility Study.
  • The MAGLEV rotor spins 2000 times per minute without mechanical wear, enabling long-term durability and reduced blood trauma.

What critics are saying

  • Supraphysiologic output risks thromboembolism or end-organ damage if hemodynamic instability persists before pivotal trial approval.
  • Failure to recruit patients for remaining EFS slots may delay pivotal trial initiation by over 12 months.
  • FDA may reject long-term TAH use if pivotal trial lacks sufficient evidence of 5-year durability, capping revenue potential.

What makes BiVACOR unique

  • BiVACOR's titanium TAH uses a single magnetically levitated rotor, eliminating valves and mechanical wear points.
  • The device provides pulsatile flow mimicking natural heartbeat without flexing diaphragms or ventricle chambers.
  • It is the first total artificial heart receiving FDA Breakthrough Device Designation as a bridge to transplant.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Life Insurance

Employee Assistance Program

401(k) Company Match

Paid Vacation

Growth & Insights

Headcount

6 month growth

0%

1 year growth

3%

2 year growth

0%